6-K - NeuroSense Therapeutics Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NeuroSense Therapeutics Ltd. announced the rescheduling of its pre-NDS meeting with Health Canada to May 2026 to incorporate additional clinical, biomarker, and survival data for PrimeC, while expecting Alzheimer’s study results in coming weeks. This strengthens the regulatory foundation and positions the company ahead of 2026 value inflection points in ALS and Alzheimer’s programs.

Key Takeaways

1Pre-NDS meeting with Health Canada rescheduled to May 2026

2Inclusion of additional emerging clinical, biomarker, and survival data in briefing package

3Alzheimer’s Disease study clinical and biomarker results expected in coming weeks

4Statistically significant 65% reduction in risk of death for PrimeC

5FDA clearance to initiate pivotal Phase 3 PARAGON trial in ALS

6Advancing PrimeC under NOC/c pathway in Canada

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE DATED MARCH 24, 2026